Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

BRIEF

published on 01/30/2025 at 00:20, 4 months 3 days ago

Protagonist Therapeutics annonce un événement destiné aux investisseurs axé sur la polycythémie vraie et le rusfertide

Essais Cliniques Rusfertide Thérapeutique Protagoniste Événement Pour Les Investisseurs Polycythémie Vraie
BRIEF

published on 01/30/2025 at 00:20, 4 months 3 days ago

Protagonist Therapeutics Announces Investor Event Focused on Polycythemia Vera and Rusfertide

Clinical Trials Investor Event Protagonist Therapeutics Rusfertide Polycythemia Vera
PRESS RELEASE

published on 01/30/2025 at 00:15, 4 months 3 days ago

Protagonist to Host Investor Event with KOL Insights on Polycythemia Vera (PV) and the Hepcidin Mimetic Rusfertide in New York on February 6, 2025
Protagonist Therapeutics to host investor event discussing Rusfertide Phase 3 VERIFY study design and Phase 2 data with key opinion leaders. Company also to provide commercial opportunity snapshot. Live Q&A session and lunch included

Investor Event Protagonist Therapeutics Rusfertide Phase 3 VERIFY Study Commercial Opportunity
BRIEF

published on 01/06/2025 at 22:10, 4 months 26 days ago

Protagonist Therapeutics annonce des primes d'encouragement à un nouveau dirigeant

Nasdaq Thérapeutique Protagoniste Options Sur Actions Primes D'encouragement Nouveau Comité Exécutif
BRIEF

published on 01/06/2025 at 22:10, 4 months 26 days ago

Protagonist Therapeutics Announces Inducement Awards to New Executive

Stock Options Nasdaq Protagonist Therapeutics Inducement Awards New Executive
PRESS RELEASE

published on 01/06/2025 at 22:05, 4 months 26 days ago

Protagonist Therapeutics Reports Granting of Inducement Awards
Protagonist Therapeutics grants inducement awards to Dr. Newman Yeilding for the role of Executive Vice President, Chief Scientific Officer, under inducement plan. Company's focus on peptide therapeutics and Phase 3 drug development

Protagonist Therapeutics Phase 3 Clinical Development Inducement Awards Peptide Therapeutics Drug Candidates
BRIEF

published on 12/19/2024 at 22:10, 5 months 13 days ago

Protagonist Therapeutics présentera ses produits à la conférence JP Morgan Healthcare

Rusfertide Thérapeutique Protagoniste Icotrokinra Développement Biopharmaceutique Conférence De JP Morgan
BRIEF

published on 12/19/2024 at 22:10, 5 months 13 days ago

Protagonist Therapeutics to Present at J.P. Morgan Healthcare Conference

Protagonist Therapeutics Rusfertide Icotrokinra Biopharmaceutical Development J.P. Morgan Conference
PRESS RELEASE

published on 12/19/2024 at 22:05, 5 months 13 days ago

Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025
Protagonist Therapeutics to present company overview at 43rd Annual J.P. Morgan Healthcare Conference. Highlights late-stage peptides in clinical development

Clinical Development Biopharmaceutical Protagonist Therapeutics J.P. Morgan Healthcare Conference Peptides
BRIEF

published on 12/09/2024 at 22:10, 5 months 23 days ago

Protagonist Therapeutics révèle des résultats prometteurs pour son étude sur le rusfertide à l'ASH 2024

Rusfertide Polycythémie Vraie Phase 2 REVIVE ASH 2024 Contrôle De L'hématocrite

Published on 06/02/2025 at 01:00, 3 hours 59 minutes ago

Sparta Capital Announces Filing of Interim Financial Statements
Published on 05/31/2025 at 06:16, 1 day 22 hours ago

Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE
Published on 05/31/2025 at 03:30, 2 days 1 hour ago

Avant Brands Inc. Announces Voting Results From 2025 Annual General Meeting of Shareholders
Published on 05/31/2025 at 01:45, 2 days 3 hours ago

GLG Life Tech Corporation Reports 2025 First Quarter Financial Results
Published on 05/30/2025 at 23:10, 2 days 5 hours ago

CORRECTION: Nextech3D.ai Migrates MAP Dynamics to AWS, Enabling Scalable AI Architecture and Accelerated Deployment

View all ACCESSWIRE

Published on 06/01/2025 at 22:26, 6 hours 32 minutes ago

KKR Increases Offer Price for Public Purchase Offer for DATAGROUP Shares conditional upon Final Acceptance Level, Best and Final Offer for DATAGROUP Shares Expires on 6 June 2025
Published on 06/01/2025 at 22:12, 6 hours 46 minutes ago

EQS-Adhoc: DATAGROUP SE: KKR Increases Offer Price for Public Purchase Offer for DATAGROUP Shares conditional upon Final Acceptance Level
Published on 06/01/2025 at 10:00, 18 hours 59 minutes ago

OPPO and the UEFA Champions League Final: Powering Football Innovation On and Off the Pitch
Published on 05/31/2025 at 21:00, 1 day 7 hours ago

Leclanché annonce le dépôt d'une demande de prolongation du délai de publication du rapport annuel 2024 et la suspension temporaire de la cotation de ses actions nominatives à la SIX Swiss Exchange
Published on 05/31/2025 at 21:00, 1 day 7 hours ago

Leclanché SA: Leclanché announces filing of request to extend the publication deadline for the 2024 Annual Report and the temporary suspension of trading of its registered shares on SIX Swiss Exchange

View all EQS

Published on 05/30/2025 at 22:00, 2 days 6 hours ago

Information sur les comptes annuels
Published on 05/30/2025 at 22:00, 2 days 6 hours ago

Information on the Annual Financial Statements
Published on 05/30/2025 at 18:14, 2 days 10 hours ago

Emova Group - Rapport annuel de Durabilité 23/24
Published on 05/28/2025 at 23:00, 4 days 5 hours ago

Standstill Commitments to hold shares of the company
Published on 05/28/2025 at 23:00, 4 days 5 hours ago

Engagements collectifs de conservation de titres de la société

View all LES ECHOS COMFI WIRE

News